- Home
- CNTX vs IFRX Comparison
CNTX vs IFRX Comparison
Compare CNTX & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- IFRX
- Stock Information
- Founded
- CNTX 2015
- IFRX 2007
- Country
- CNTX United States
- IFRX Germany
- Employees
- CNTX N/A
- IFRX N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- IFRX Health Care
- Exchange
- CNTX Nasdaq
- IFRX Nasdaq
- Market Cap
- CNTX 78.0M
- IFRX 65.8M
- IPO Year
- CNTX 2021
- IFRX 2017
- Fundamental
- Price
- CNTX $0.65
- IFRX $0.81
- Analyst Decision
- CNTX Strong Buy
- IFRX Strong Buy
- Analyst Count
- CNTX 5
- IFRX 4
- Target Price
- CNTX $5.50
- IFRX $7.75
- AVG Volume (30 Days)
- CNTX 330.3K
- IFRX 328.2K
- Earning Date
- CNTX 08-06-2025
- IFRX 08-07-2025
- Dividend Yield
- CNTX N/A
- IFRX N/A
- EPS Growth
- CNTX N/A
- IFRX N/A
- EPS
- CNTX N/A
- IFRX N/A
- Revenue
- CNTX N/A
- IFRX $140,242.00
- Revenue This Year
- CNTX N/A
- IFRX N/A
- Revenue Next Year
- CNTX N/A
- IFRX $6,309.47
- P/E Ratio
- CNTX N/A
- IFRX N/A
- Revenue Growth
- CNTX N/A
- IFRX 30.90
- 52 Week Low
- CNTX $0.49
- IFRX $0.71
- 52 Week High
- CNTX $2.75
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- CNTX 51.44
- IFRX 37.96
- Support Level
- CNTX $0.62
- IFRX $0.78
- Resistance Level
- CNTX $0.70
- IFRX $0.83
- Average True Range (ATR)
- CNTX 0.04
- IFRX 0.04
- MACD
- CNTX 0.01
- IFRX 0.02
- Stochastic Oscillator
- CNTX 67.29
- IFRX 60.00
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.